Cryoport to Report First Quarter 2025 Financial Results on May 7, 2025
Cryoport (CYRX), a global life sciences supply chain solutions provider, has scheduled its first quarter 2025 financial results announcement for May 7, 2025 after U.S. markets close. The company will release its earnings report alongside a comprehensive document titled 'Cryoport First Quarter 2025 in Review' at 4:05 p.m. ET, providing detailed financial and operational performance updates.
Management will host a Q&A conference call at 5:00 p.m. ET the same day, accompanied by a slide deck presentation. The call will be accessible via U.S. dial-in (1-800-717-1738) and International dial-in (1-646-307-1865) using Conference ID: 1180684. A webcast replay will be available until May 14, 2025.
Cryoport (CYRX), fornitore globale di soluzioni per la catena di approvvigionamento nel settore delle scienze della vita, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 7 maggio 2025 dopo la chiusura dei mercati statunitensi. L'azienda pubblicherà il rapporto sugli utili insieme a un documento dettagliato intitolato 'Cryoport Primo Trimestre 2025 in Rassegna' alle 16:05 ET, fornendo aggiornamenti approfonditi sulle performance finanziarie e operative.
La direzione terrà una conference call con sessione di domande e risposte alle 17:00 ET dello stesso giorno, accompagnata da una presentazione in formato slide. La chiamata sarà accessibile tramite numero statunitense (1-800-717-1738) e internazionale (1-646-307-1865) utilizzando l'ID conferenza: 1180684. Una replica in webcast sarà disponibile fino al 14 maggio 2025.
Cryoport (CYRX), proveedor global de soluciones para la cadena de suministro en ciencias de la vida, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 7 de mayo de 2025 después del cierre de los mercados estadounidenses. La compañía publicará su informe de ganancias junto con un documento detallado titulado 'Cryoport Primer Trimestre 2025 en Revisión' a las 16:05 ET, ofreciendo actualizaciones detalladas sobre el desempeño financiero y operativo.
La dirección realizará una llamada de preguntas y respuestas a las 17:00 ET ese mismo día, acompañada de una presentación en diapositivas. La llamada será accesible mediante marcación en EE.UU. (1-800-717-1738) e internacional (1-646-307-1865) usando el ID de conferencia: 1180684. Una repetición en webcast estará disponible hasta el 14 de mayo de 2025.
Cryoport (CYRX)는 생명과학 공급망 솔루션을 제공하는 글로벌 기업으로, 2025년 1분기 재무실적 발표를 2025년 5월 7일 미국 시장 마감 후에 예정하고 있습니다. 회사는 16:05 ET에 'Cryoport 2025년 1분기 검토'라는 종합 문서와 함께 실적 보고서를 발표하여 재무 및 운영 성과에 대한 상세한 업데이트를 제공합니다.
경영진은 같은 날 17:00 ET에 질의응답 컨퍼런스 콜을 진행하며 슬라이드 자료도 함께 제공할 예정입니다. 콜은 미국 내 전화(1-800-717-1738) 및 국제 전화(1-646-307-1865)를 통해 컨퍼런스 ID: 1180684로 참여할 수 있습니다. 웹캐스트 재방송은 2025년 5월 14일까지 이용 가능합니다.
Cryoport (CYRX), fournisseur mondial de solutions pour la chaîne d'approvisionnement en sciences de la vie, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 7 mai 2025 après la fermeture des marchés américains. La société publiera son rapport de résultats accompagné d'un document complet intitulé 'Cryoport Premier Trimestre 2025 en Revue' à 16h05 ET, fournissant des mises à jour détaillées sur les performances financières et opérationnelles.
La direction tiendra une conférence téléphonique avec questions-réponses à 17h00 ET le même jour, accompagnée d'une présentation en diaporama. L'appel sera accessible via les numéros d'accès aux États-Unis (1-800-717-1738) et internationaux (1-646-307-1865) avec l'ID de conférence : 1180684. Une rediffusion en webcast sera disponible jusqu'au 14 mai 2025.
Cryoport (CYRX), ein globaler Anbieter von Lieferkettenlösungen für die Biowissenschaften, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 7. Mai 2025 nach Börsenschluss in den USA geplant. Das Unternehmen wird seinen Gewinnbericht zusammen mit einem umfassenden Dokument mit dem Titel 'Cryoport Erstes Quartal 2025 Rückblick' um 16:05 Uhr ET veröffentlichen und detaillierte Updates zur finanziellen und operativen Leistung bieten.
Das Management wird am selben Tag um 17:00 Uhr ET eine Q&A-Konferenzschaltung mit einer begleitenden Präsentation abhalten. Der Anruf ist über US-Dial-In (1-800-717-1738) und International Dial-In (1-646-307-1865) mit der Konferenz-ID: 1180684 zugänglich. Eine Webcast-Wiederholung wird bis zum 14. Mai 2025 verfügbar sein.
- None.
- None.
In addition to the earnings release, a document titled "Cryoport First Quarter 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business update, will be issued at 4:05 p.m. ET on Wednesday, May 7, 2025. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call the same day at 5:00 p.m. ET. The conference call will be in the format of a questions and answers session and will address questions members of the investment community have regarding the Company's reported results. A slide deck will accompany the call.
Conference Call Information
Date: | Wednesday, May 7, 2025 |
Time: | 5:00 p.m. ET |
Dial-in numbers: | 1-800-717-1738 ( |
Confirmation code: | Request the "Cryoport Call" or Conference ID: 1180684 |
Live webcast: | 'Investor Relations' section at www.cryoportinc.com or click here. Please allow 10 minutes prior to the call to visit this site to download and install any |
The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until May 14, 2025. To access the replay, dial 1-844-512-2921 (
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the Life Sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-first-quarter-2025-financial-results-on-may-7-2025-302436963.html
SOURCE Cryoport, Inc.
FAQ
When will Cryoport (CYRX) release its Q1 2025 earnings?
How can investors join Cryoport's Q1 2025 earnings call?
How long will Cryoport's Q1 2025 earnings call replay be available?
What additional materials will Cryoport provide with its Q1 2025 earnings?
